These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

512 related articles for article (PubMed ID: 29602981)

  • 1. Population pharmacokinetics of vancomycin and AUC-guided dosing in Chinese neonates and young infants.
    Chen Y; Wu D; Dong M; Zhu Y; Lu J; Li X; Chen C; Li Z
    Eur J Clin Pharmacol; 2018 Jul; 74(7):921-930. PubMed ID: 29602981
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association between vancomycin trough concentration and area under the concentration-time curve in neonates.
    Frymoyer A; Hersh AL; El-Komy MH; Gaskari S; Su F; Drover DR; Van Meurs K
    Antimicrob Agents Chemother; 2014 Nov; 58(11):6454-61. PubMed ID: 25136027
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Population pharmacokinetics of vancomycin in premature Malaysian neonates: identification of predictors for dosing determination.
    Lo YL; van Hasselt JG; Heng SC; Lim CT; Lee TC; Charles BG
    Antimicrob Agents Chemother; 2010 Jun; 54(6):2626-32. PubMed ID: 20385872
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of vancomycin dosing regimens in preterm and term neonates using Monte Carlo simulations.
    Mehrotra N; Tang L; Phelps SJ; Meibohm B
    Pharmacotherapy; 2012 May; 32(5):408-19. PubMed ID: 22488303
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Establishment of a population pharmacokinetics model of vancomycin in 94 infants with septicemia and its application in individualized therapy.
    Li Z; Li H; Wang C; Jiao Z; Xu F; Sun H
    BMC Pharmacol Toxicol; 2021 May; 22(1):26. PubMed ID: 33947475
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessment of Vancomycin Pharmacokinetics and Dose Regimen Optimisation in Preterm Neonates.
    Mulubwa M; Griesel HA; Mugabo P; Dippenaar R; van Wyk L
    Drugs R D; 2020 Jun; 20(2):105-113. PubMed ID: 32266599
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development and external evaluation of a population pharmacokinetic model for continuous and intermittent administration of vancomycin in neonates and infants using prospectively collected data.
    Germovsek E; Osborne L; Gunaratnam F; Lounis SA; Busquets FB; Standing JF; Sinha AK
    J Antimicrob Chemother; 2019 Apr; 74(4):1003-1011. PubMed ID: 30668696
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vancomycin pharmacokinetics in preterm neonates and the prediction of adult clearance.
    Anderson BJ; Allegaert K; Van den Anker JN; Cossey V; Holford NH
    Br J Clin Pharmacol; 2007 Jan; 63(1):75-84. PubMed ID: 16869817
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vancomycin dosing assessment in intensive care unit patients based on a population pharmacokinetic/pharmacodynamic simulation.
    Revilla N; Martín-Suárez A; Pérez MP; González FM; Fernández de Gatta Mdel M
    Br J Clin Pharmacol; 2010 Aug; 70(2):201-12. PubMed ID: 20653673
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Population pharmacokinetics and dose optimization of vancomycin in neonates.
    Lee SM; Yang S; Kang S; Chang MJ
    Sci Rep; 2021 Mar; 11(1):6168. PubMed ID: 33731764
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessment of optimal initial dosing regimen with vancomycin pharmacokinetics model in very low birth weight neonates.
    Kato H; Hagihara M; Nishiyama N; Koizumi Y; Mikamo H; Matsuura K; Yamagishi Y
    J Infect Chemother; 2017 Mar; 23(3):154-160. PubMed ID: 28017667
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Population pharmacokinetic meta-analysis of individual data to design the first randomized efficacy trial of vancomycin in neonates and young infants.
    Jacqz-Aigrain E; Leroux S; Thomson AH; Allegaert K; Capparelli EV; Biran V; Simon N; Meibohm B; Lo YL; Marques R; Peris JE; Lutsar I; Saito J; Nakamura H; van den Anker JN; Sharland M; Zhao W
    J Antimicrob Chemother; 2019 Aug; 74(8):2128-2138. PubMed ID: 31049551
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Population pharmacokinetics of piperacillin/tazobactam in neonates and young infants.
    Li Z; Chen Y; Li Q; Cao D; Shi W; Cao Y; Wu D; Zhu Y; Wang Y; Chen C
    Eur J Clin Pharmacol; 2013 Jun; 69(6):1223-33. PubMed ID: 23354809
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluating the Relationship between Vancomycin Trough Concentration and 24-Hour Area under the Concentration-Time Curve in Neonates.
    Tseng SH; Lim CP; Chen Q; Tang CC; Kong ST; Ho PC
    Antimicrob Agents Chemother; 2018 Apr; 62(4):. PubMed ID: 29358290
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Optimisation of vancomycin exposure in neonates based on the best level of evidence.
    Dao K; Guidi M; André P; Giannoni E; Basterrechea S; Zhao W; Fuchs A; Pfister M; Buclin T; Csajka C
    Pharmacol Res; 2020 Apr; 154():104278. PubMed ID: 31108184
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improved vancomycin dosing in children using area under the curve exposure.
    Le J; Bradley JS; Murray W; Romanowski GL; Tran TT; Nguyen N; Cho S; Natale S; Bui I; Tran TM; Capparelli EV
    Pediatr Infect Dis J; 2013 Apr; 32(4):e155-63. PubMed ID: 23340565
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Population Pharmacokinetics and Pharmacodynamic Target Attainment of Vancomycin in Neonates on Extracorporeal Life Support.
    Cies JJ; Moore WS; Nichols K; Knoderer CA; Carella DM; Chopra A
    Pediatr Crit Care Med; 2017 Oct; 18(10):977-985. PubMed ID: 28650363
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Population pharmacokinetic analysis of vancomycin in neonates. A new proposal of initial dosage guideline.
    Marqués-Miñana MR; Saadeddin A; Peris JE
    Br J Clin Pharmacol; 2010 Nov; 70(5):713-20. PubMed ID: 21039765
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Population pharmacokinetics of ciprofloxacin in neonates and young infants less than three months of age.
    Zhao W; Hill H; Le Guellec C; Neal T; Mahoney S; Paulus S; Castellan C; Kassai B; van den Anker JN; Kearns GL; Turner MA; Jacqz-Aigrain E;
    Antimicrob Agents Chemother; 2014 Nov; 58(11):6572-80. PubMed ID: 25155587
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of Vancomycin Dose Needed to Achieve 24-Hour Area Under the Concentration-Time Curve to Minimum Inhibitory Concentration Ratio Greater Than or Equal to 400 Using Pharmacometric Approaches in Pediatric Intensive Care Patients.
    Jung D; Kishk OA; Bhutta AT; Cummings GE; El Sahly HM; Virk MK; Moffett BS; Morris Daniel JL; Watanabe A; Fishbane N; Kotloff KL; Gu K; Ghazaryan V; Gobburu JVS; Akcan-Arikan A; Campbell JD
    Crit Care Explor; 2024 Oct; 6(10):e1159. PubMed ID: 39352409
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.